Table 1 Tumour samples are listed along with their pathogenic variant detected either by diagnostic test or by whole genome sequencing where known (column 2)
|  | (ALL) N = 52 | N |
|---|---|---|
Group | Â | 52 |
 HRAS | 2 (3.85%) |  |
 IDH3B | 1 (1.92%) |  |
 NF1 | 1 (1.92%) |  |
 Normal | 2 (3.85%) |  |
 RET | 1 (1.92%) |  |
 SDHA | 1 (1.92%) |  |
 SDHB | 14 (26.9%) |  |
 SDHD | 5 (9.62%) |  |
 Sporadic | 20 (38.5%) |  |
 VHL | 5 (9.62%) |  |
Location | Â | 50 |
 EAPGL | 21 (42.0%) |  |
 HNPGL | 7 (14.0%) |  |
 PCC | 22 (44.0%) |  |
Metastatic | Â | 50 |
 No | 20 (40.0%) |  |
 Unknown | 22 (44.0%) |  |
 Yes | 8 (16.0%) |  |
Primary | Â | 50 |
 No | 4 (8.00%) |  |
 Unknown | 22 (44.0%) |  |
 Yes | 24 (48.0%) |  |
Recurring | Â | 50 |
 No | 21 (42.0%) |  |
 Unknown | 22 (44.0%) |  |
 Yes | 7 (14.0%) |  |
Clinically aggressive | Â | 50 |
 No | 17 (34.0%) |  |
 Unknown | 22 (44.0%) |  |
 Yes | 11 (22.0%) |  |
ATRX double mutation: | Â | 50 |
 No | 24 (48.0%) |  |
 Unknown | 22 (44.0%) |  |
 Yes | 4 (8.00%) |  |
Cluster | Â | 52 |
 Cluster 1A | 21 (40.4%) |  |
 Cluster 1B | 5 (9.62%) |  |
 Cluster 2 | 4 (7.69%) |  |
 Normal | 2 (3.85%) |  |
 Sporadic | 20 (38.5%) |  |
Sex | Â | 52 |
 F | 15 (28.8%) |  |
 M | 21 (40.4%) |  |
 Unknown | 16 (30.8%) |  |
Tissue | Â | 52 |
 Normal adrenal medulla | 2 (3.85%) |  |
 Tumour | 50 (96.2%) |  |